Why Zai Lab (ZLAB) is on investors’ radar

Zai Lab (ZLAB) has been drawing attention after recent share price pressure, with the stock down 4.3% over the past day and 17.9% over the past month, prompting investors to reassess its fundamentals.

At a recent close of US$17.69 and a market value of about US$2.0b, the biopharmaceutical company reports annual revenue of US$453.28 million and a net loss of US$178.12 million, reflecting an early stage earnings profile.

Recent trading has been weak, with the share price down 17.9% over the past month and the 1 year total shareholder return declining 43.3%. This suggests sentiment toward Zai Lab has cooled even as investors scrutinise its revenue scale against ongoing losses.

If you are reassessing your healthcare exposure after Zai Lab’s recent moves, this could be a useful moment to scan other opportunities in the sector through our 39 healthcare AI stocks

With Zai Lab trading at US$17.69, a reported intrinsic discount of 77.7% and analyst targets sitting higher, the real question is whether the recent weakness signals an undervalued entry point or a market that already sees limited future growth.

Most Popular Narrative: 49.9% Undervalued

At a last close of $17.69 versus a narrative fair value of $35.34, the current price sits well below the level implied by widely followed forecasts, which lean heavily on Zai Lab’s pipeline and revenue potential.

Multiple high-potential product launches and label expansions over the next 12-18 months (including VYVGART, bemarituzumab, KarXT, TIVDAK, Tumor Treating Fields), combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.

Curious what kind of revenue expansion, margin shift and valuation multiple are built into that view? The narrative leans on specific growth rates, profitability targets and a future earnings multiple that is far above the broader biotech group, all tied to a detailed set of product roll out timelines and reimbursement assumptions.

Result: Fair Value of $35.34 (UNDERVALUED)

However, this upbeat story still hinges on China pricing and reimbursement risks, along with ongoing competition that could pressure both revenue expectations and the implied future P/E multiple.

Next Steps

With sentiment clearly split between concern over risks and interest in potential rewards, this is a moment to move quickly and weigh the trade off yourself by using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Zai Lab has sharpened your focus, do not stop here. Use the Simply Wall St Screener to quickly spot fresh candidates that could better fit your goals.

• Target potential mispricings by scanning a curated mix of quality stocks trading below estimated value through the 46 high quality undervalued stocks.
• Prioritise resilience by filtering for companies with sturdy finances using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot opportunities others might be missing by reviewing a focused screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.